LIP
GILD icon

Liontrust Investment Partners’s Gilead Sciences GILD Stock Holding History

Liontrust Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-103,904
Closed -$8.42M – 202
2023
Q4 		$8.42M Sell
103,904
-10,681
-9% -$831K 0.12% 101
2023
Q3 		$8.59M Hold
114,585
– – 0.14% 96
2023
Q2 		$8.83M Buy
+114,585
New +$9.14M 0.13% 100

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Liontrust Investment Partners's GILD Position: Q1 2024 in Review

Liontrust Investment Partners sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 103,904 shares — an estimated $8.42M sold.

Liontrust Investment Partners first reported a position in GILD in Q2 2023 and held it in 3 quarters. The position peaked at $8.83M in Q2 2023. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Liontrust Investment Partners reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • Liontrust Investment Partners sold 103,904 Gilead Sciences shares in Q1 2024, an estimated $8.42M.
  • Liontrust Investment Partners first reported a position in Gilead Sciences in Q2 2023 and held it in 3 quarters.
  • Liontrust Investment Partners's Gilead Sciences position peaked at $8.83M in Q2 2023.
  • 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Liontrust Investment Partners's 13F filing for Q1 2024, filed 10 May 2024.